½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting



»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹CDR2¶à¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • Íÿ¹CDR2¶à¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW5675
    • Ó¦Óà : ½öÓÃÓÚ¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul/200ul/25ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ£ºÍÿ¹CDR2¶à¿Ë¡¿¹Ìå

Ó¢ÎÄÃû³Æ£º
Anti-CDR2 rabbit polyclonal antibody

±ð      Ãû£º Yo; CDR62

Ïà¹ØÀà±ð£º Ò»¿¹

¿¹      Ô­£º CDR2

´¢      ´æ£º Àä¶³£¨-20¡æ£©

ËÞ      Ö÷£º
Rabbit

·´Ó¦ÖÖÊô£º Human, Mouse

±ê ¼Ç Î Unconjugate

¿Ë¡ÀàÐÍ£º rabbit polyclonal

¼¼Êõ¹æ¸ñ

Background:

CDR2 (cerebellar degeneration-related protein 2), also referred to as Yo or CDR62, is a 545 amino acid protein that is associated with the development of paraneoplastic cerebellar degeneration (PCD). PCD, an immune-mediated syndrome, belongs to a heterogeneous group of rare paraneoplastic neurologic disorders affecting the neurological system. PCD is characterized by subacute cerebellar ataxia and occurs mainly in patients with ovarian, uterine, fallopian tube or breast cancer.

Applications:

ELISA, IHC

Name of antibody:

CDR2

Immunogen:

Fusion protein of human CDR2

Full name:

cerebellar degeneration-related protein 2, 62kDa

Synonyms£º

Yo; CDR62

SwissProt:

Q01850

ELISA Recommended dilution:

2000-5000

IHC positive control:

Human thyroid cancer and human liver cancer

IHC Recommend dilution:

50-200




    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
      ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿